CompoAtlas

Cardio Protect

Withdrawn from the US market on 17 January 2020 (according to the DSLD)

BioGenesis Nutraceuticals, food supplement from the US market

Label withdrawn from the US market. Cardio Protect (BioGenesis Nutraceuticals), a food supplement au code-barres 812806102648, is described by its US market label. If sold in France, it would be subject to 4 points of French or European regulation, detailed below. Doses of folates, niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
BioGenesis Nutraceuticals
Barcode
812806102648
Form
Capsule
One serving
1 capsule
Servings
up to 3 servings per day
Other ingredients (in English, as written)
Cellulose, Stearic Acid, Silica
Ingredient (as written, in English)CategoryPer serving
Vitamin CVitamin175 mg
Vitamin EVitamin60 UI
Vitamin K2Vitamin25 µg
ThiamineVitamin15 mg
RiboflavinVitamin15 mg
NiacinVitamin225 mg
Vitamin B6Vitamin25 mg
FolateVitamin400 µg
Vitamin B12Vitamin150 µg
MagnesiumMineral70 mg
SeleniumMineral150 µg
PotassiumMineral70 mg
Pomegranate fruit extract (Punica granatum)Plant150 mg
N-Acetyl-L-CysteineOther substance100 mg
TrimethylglycineOther substance100 mg
Cocoa bean extract (Theobroma cacao)Plant90 mg
Acetyl L-carnitineOther substance80 mg
L-CarnitineOther substance80 mg
L-LysineAmino acid80 mg
L-ProlineAmino acid80 mg
L-TaurineOther substance80 mg
ResveratrolOther substance80 mg
InositolOther substance75 mg
Coenzyme Q10Other substance50 mg
Hawthorn leaf extractPlant50 mg
Alpha R-lipoic acidOther substance15 mg

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

Other versions of this label

The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Pomegranate fruit extract
    Read the warning, when it applies and the studies cited
  • L-Carnitine
    Read the warning, when it applies and the studies cited

    L-CARNITINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (CPS 2008).

    Sources cited by Health Canada (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a seizure disorder (CPS 2008).

    Sources cited by Health Canada (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 25 July 2025

  • Coenzyme Q10
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : BioGenesis Nutraceuticals

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Cardio Protect : étiquette retirée du marché américain (BioGenesis Nutraceuticals): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/812806102648-cardio-protect-biogenesis-nutraceuticals, updated 17 January 2020.

List recorded in 2013. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line